Lugh@futurology.todayM to Futurology@futurology.todayEnglish · 20 days agoVerve is developing a pipeline of gene editing medicines to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime.investor.lilly.comexternal-linkmessage-square0linkfedilinkarrow-up17arrow-down10cross-posted to: futurology@futurology.today
arrow-up17arrow-down1external-linkVerve is developing a pipeline of gene editing medicines to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime.investor.lilly.comLugh@futurology.todayM to Futurology@futurology.todayEnglish · 20 days agomessage-square0linkfedilinkcross-posted to: futurology@futurology.today
